Abstract: The present invention provides lymphatic system-directing lipid prodrugs, pharmaceutical compositions thereof, methods of producing such prodrugs and compositions, and methods of improving the bioavailability or other properties of a therapeutic agent that comprises part of the lipid prodrug. The present invention also provides methods of treating a disease, disorder, or condition such as those disclosed herein, comprising administering to a patient in need thereof a disclosed lipid prodrug or a pharmaceutical composition thereof.

Abstract: The present invention provides lymphatic system-directing lipid prodrugs, pharmaceutical compositions thereof, methods of producing such prodrugs and compositions, as well as methods of improving the bioavailability or other properties of a therapeutic agent that comprises part of the lipid prodrug. The present invention also provides methods of treating a disease, disorder, or condition such as those disclosed herein, comprising administering to a patient in need thereof a provided lipid prodrug or a pharmaceutical composition thereof.

Abstract: The present invention provides lymphatic system-directing lipid prodrugs, pharmaceutical compositions thereof, methods of producing such prodrugs and compositions, as well as methods of improving the bioavailability or other properties of a therapeutic agent that comprises part of the lipid prodrug. The present invention also provides methods of treating a disease, disorder, or condition such as those disclosed herein, comprising administering to a patient in need thereof a disclosed lipid prodrug or a pharmaceutical composition thereof.

Abstract: The present invention provides lymphatic system-directing lipid prodrugs, pharmaceutical compositions thereof, methods of producing such prodrugs and compositions, as well as methods of improving the bioavailability or other properties of a therapeutic agent that comprises part of the lipid prodrug. The present invention also provides methods of treating a disease, disorder, or condition such as those disclosed herein, comprising administering to a patient in need thereof a disclosed lipid prodrug or a pharmaceutical composition thereof.

Abstract: The present invention provides lymphatic system-directing lipid prodrugs, pharmaceutical compositions thereof, methods of producing such prodrugs and compositions, and methods of improving the bioavailability or other properties of a therapeutic agent that comprises part of the lipid prodrug. The present invention also provides methods of treating a disease, disorder, or condition such as those disclosed herein, comprising administering to a patient in need thereof a disclosed lipid prodrug or a pharmaceutical composition thereof.

Abstract: The present invention provides lymphatic system-directing lipid prodrugs, pharmaceutical compositions thereof, methods of producing such prodrugs and compositions, and methods of improving the bioavailability or other properties of a therapeutic agent that comprises part of the lipid prodrug. The present invention also provides methods of treating a disease, disorder, or condition such as those disclosed herein, comprising administering to a patient in need thereof a disclosed lipid prodrug or a pharmaceutical composition thereof.

Abstract: The present invention provides lymphatic system-directing lipid prodrugs, pharmaceutical compositions thereof, methods of producing such prodrugs and compositions, and methods of improving the bioavailability or other properties of a therapeutic agent that comprises part of the lipid prodrug. The present invention also provides methods of treating a disease, disorder, or condition such as those disclosed herein, comprising administering to a patient in need thereof a disclosed lipid prodrug or a pharmaceutical composition thereof.

Abstract: The present invention provides lymphatic system-directing lipid prodrugs, pharmaceutical compositions thereof, methods of producing such prodrugs and compositions, as well as methods of improving the bioavailability or other properties of a therapeutic agent that comprises part of the lipid prodrug. The present invention also provides methods of treating a disease, disorder, or condition such as those disclosed herein, comprising administering to a patient in need thereof a provided lipid prodrug or a pharmaceutical composition thereof.

Abstract: The present invention provides lymphatic system-directing lipid prodrugs, pharmaceutical compositions thereof, methods of producing such prodrugs and compositions, as well as methods of improving the bioavailability or other properties of a therapeutic agent that comprises part of the lipid prodrug. The present invention also provides methods of treating a disease, disorder, or condition such as those disclosed herein, comprising administering to a patient in need thereof a disclosed lipid prodrug or a pharmaceutical composition thereof.

Abstract: The present invention provides lymphatic system-directing lipid prodrugs, pharmaceutical compositions thereof, methods of producing such prodrugs and compositions, and methods of improving the bioavailability or other properties of a therapeutic agent that comprises part of the lipid prodrug. The present invention also provides methods of treating a disease, disorder, or condition such as those disclosed herein, comprising administering to a patient in need thereof a disclosed lipid prodrug or a pharmaceutical composition thereof.

Abstract: Systems and methods are provided for the implementation of personalized cognitive training. As an example, a processor-implemented method is provided for enhancing cognitive abilities of a user by personalizing cognitive training regimens through difficulty progression. The method includes: performing a cognitive assessment of a user using a set of assessment tasks; estimating a maximal performance of the user related to the set of assessment tasks; determining a performance range based at least in part on the maximal performance of the user; dividing the performance range into a plurality of progress gates, the plurality of progress gates corresponding to a plurality of task difficulty levels; selecting a first progress gate within the performance range; generating a first set of training tasks associated with the first progress gate; and collecting the user's first training responses to the first set of training tasks.

Abstract: A system for inducing a physical state in a user. The system includes a sensor associated with the user, an audio output device, and a computer. The computer obtains, from a database, an identification of a type of music associated with a first phase of sleep, and determines, based on data from the sensor, that a user is in a second phase of sleep. Music of the type associated with the first phase of sleep is selected, and the selected music is output to the user through the audio output device.

Abstract: A predictive method may include determining the strength of a relationship between a user's health state and the user's consumption of media content having one or more features, based on health data and media consumption data corresponding to user consumption of media content items having the feature(s), and predicting an effect of consuming a media content item on the user's health. The prediction may be based on a determination that the strength of the relationship between the health state and the consumption of media content having the one or more features exceeds a threshold strength. A diagnostic method may include determining whether a media consumption signature associated with a health condition matches media consumption data for a population, and diagnosing the population with the health condition based on a determination that the media consumption signature associated with the health condition matches the media consumption data for the population.

Abstract: Systems and methods are provided for the implementation of personalized cognitive training. As an example, a processor-implemented method is provided for enhancing cognitive abilities of a user by personalizing cognitive training regimens through difficulty progression. The method includes: performing a cognitive assessment of a user using a set of assessment tasks; estimating a maximal performance of the user related to the set of assessment tasks; determining a performance range based at least in part on the maximal performance of the user; dividing the performance range into a plurality of progress gates, the plurality of progress gates corresponding to a plurality of task difficulty levels; selecting a first progress gate within the performance range; generating a first set of training tasks associated with the first progress gate; and collecting the user's first training responses to the first set of training tasks.

Abstract: A predictive method may include determining the strength of a relationship between a user's health state and the user's consumption of media content having one or more features, based on health data and media consumption data corresponding to user consumption of media content items having the feature(s), and predicting an effect of consuming a media content item on the user's health. The prediction may be based on a determination that the strength of the relationship between the health state and the consumption of media content having the one or more features exceeds a threshold strength. A diagnostic method may include determining whether a media consumption signature associated with a health condition matches media consumption data for a population, and diagnosing the population with the health condition based on a determination that the media consumption signature associated with the health condition matches the media consumption data for the population.